JACOB HAROLD 4
4 · NanoVibronix, Inc. · Filed Dec 4, 2023
Insider Transaction Report
Form 4
JACOB HAROLD
DirectorChief Medical Officer
Transactions
- Award
Option to Purchase Common Stock
2023-11-15+3,333→ 3,333 totalExercise: $1.24Exp: 2033-11-15→ Common Stock (3,333 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2023-11-29−2,500→ 0 totalExercise: $20.20Exp: 2031-12-29→ Common Stock (2,500 underlying) - Disposition to Issuer
Option to Purchase Common Stock
2023-11-29−2,500→ 0 totalExercise: $8.94Exp: 2032-09-13→ Common Stock (2,500 underlying)
Footnotes (4)
- [F1]100% of the option vested on November 15, 2023, in accordance with that certain option agreement entered into by and between the Issuer and the reporting person and the NanoVibronix, Inc. 2014 Long-Term Incentive Plan.
- [F2]25% of the option vested on December 29, 2021 (the "2021 Date of Grant"), with an additional 25% to vest on the three-month anniversary of the 2021 Date of Grant, a further 25% to vest on the six-month anniversary of the 2021 Date of Grant, and the final 25% to vest on the nine-month anniversary of the 2021 Date of Grant, in accordance with that certain option agreement entered into by and between the Issuer and the reporting person and the NanoVibronix, Inc. 2014 Long-Term Incentive Plan.
- [F3]25% of the option vested on September 13, 2022 (the "2022 Date of Grant"), with an additional 25% to vest on the three-month anniversary of the 2022 Date of Grant, a further 25% to vest on the six-month anniversary of the 2022 Date of Grant, and the final 25% to vest on the nine-month anniversary of the 2022 Date of Grant, in accordance with that certain option agreement entered into by and between the Issuer and the reporting person and the NanoVibronix, Inc. 2014 Long-Term Incentive Plan.
- [F4]The options were canceled by mutual agreement of the reporting person and NanoVibronix, Inc. The reporting person received $1.00 as the aggregate consideration for the cancellations.